ACET Stock Summary and Trading Ideas (Adicet Bio | NASDAQ:ACET)

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio trades on the NASDAQ stock market under the symbol ACET.

As of January 30, 2026, ACET stock price declined to $7.99 with 169,928 million shares trading.

ACET has a beta of 1.65, meaning it tends to be more sensitive to market movements. ACET has a correlation of 0.15 to the broad based SPY ETF.

ACET has a market cap of $1.22 billion. This is considered a Small Cap stock.

In the last 3 years, ACET traded as high as $152.40 and as low as $7.15.

The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, VXF.

ACET has underperformed the market in the last year with a price return of -43.9% while the SPY ETF gained +15.6%. ACET has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.9% and -3.5%, respectively, while the SPY returned +2.1% and 0.0%, respectively.

ACET support price is $8.14 and resistance is $8.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET shares will trade within this expected range on the day.